title: Managing adverse effects and drug-drug interactions of antiplatelet agents.
abstract: Antiplatelet therapies have reduced the frequency of adverse events associated with plaque rupture in several clinical situations. These therapies include established antiplatelet agents (such as aspirin, clopidogrel, or glycoprotein IIb/IIIa inhibitors) as well as new agents (such as prasugrel and ticagrelor). In this Review, we address the most important adverse events of antiplatelet therapy, including hemorrhage, hematologic reactions, and dyspnea. We discuss strategies to reduce the incidence of complications and outline potential methods to manage adverse reactions. Interactions between antiplatelet agents and other drugs--such as proton-pump inhibitors, calcium-channel blockers, statins, warfarin, or NSAIDs--are also addressed, as well as specific issues relating to the use of antiplatelet therapies in elderly patients.
authors.affiliation: Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, J2-3 Cleveland, OH 44195, USA.
authors.forename: Arun
authors.initials: A
authors.lastname: Kalyanasundaram
authors.forename: A Michael
authors.initials: AM
authors.lastname: Lincoff
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D004347:Drug Interactions; D004417:Dyspnea / Q000139:chemically induced / Q000628:therapy; D006402:Hematologic Diseases / Q000139:chemically induced / Q000628:therapy; D006470:Hemorrhage / Q000139:chemically induced / Q000628:therapy; D006801:Humans; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D019338:Polypharmacy; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D010975:Platelet Aggregation Inhibitors